Acorah Software Products - Accounts Production 19.3.550 false true 31 October 2024 1 November 2023 false 1 November 2024 31 October 2025 31 October 2025 08273797 Mr Jose Manuel Lopez Perez iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 08273797 2024-10-31 08273797 2025-10-31 08273797 2024-11-01 2025-10-31 08273797 frs-core:CurrentFinancialInstruments 2025-10-31 08273797 frs-core:ShareCapital 2025-10-31 08273797 frs-core:RetainedEarningsAccumulatedLosses 2025-10-31 08273797 frs-bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 08273797 frs-bus:FilletedAccounts 2024-11-01 2025-10-31 08273797 frs-bus:SmallEntities 2024-11-01 2025-10-31 08273797 frs-bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 08273797 frs-bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 08273797 frs-core:UnlistedNon-exchangeTraded 2025-10-31 08273797 frs-core:UnlistedNon-exchangeTraded 2024-10-31 08273797 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-10-31 08273797 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-10-31 08273797 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-10-31 08273797 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-10-31 08273797 frs-bus:Director1 2024-11-01 2025-10-31 08273797 frs-countries:EnglandWales 2024-11-01 2025-10-31 08273797 2023-10-31 08273797 2024-10-31 08273797 2023-11-01 2024-10-31 08273797 frs-core:CurrentFinancialInstruments 2024-10-31 08273797 frs-core:ShareCapital 2024-10-31 08273797 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31
Registered number: 08273797
ND PHARMA & BIOTECH LTD
Unaudited Financial Statements
For The Year Ended 31 October 2025
Aster & Trujillo
3-7 Temple Avenue
Suite 140 Temple Chambers
London
EC4Y 0DA
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2
Page 1
Balance Sheet
Registered number: 08273797
2025 2024
Notes £ £ £ £
FIXED ASSETS
Investments 4 1,549,225 1,549,225
1,549,225 1,549,225
CURRENT ASSETS
Debtors 5 210,002,660 210,002,660
210,002,660 210,002,660
Creditors: Amounts Falling Due Within One Year 6 (312,157 ) (310,855 )
NET CURRENT ASSETS (LIABILITIES) 209,690,503 209,691,805
TOTAL ASSETS LESS CURRENT LIABILITIES 211,239,728 211,241,030
NET ASSETS 211,239,728 211,241,030
CAPITAL AND RESERVES
Called up share capital 7 210,000,100 210,000,100
Profit and Loss Account 1,239,628 1,240,930
SHAREHOLDERS' FUNDS 211,239,728 211,241,030
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Jose Manuel Lopez Perez
Director
30/07/2026
The notes on page 2 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
ND PHARMA & BIOTECH LTD is a private company, limited by shares, incorporated in England & Wales, registered number 08273797 . The registered office is 87 Chancery Lane, Third Floor, A&T, London, WC2A 1ET.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Investments
Unlisted
£
Cost or Valuation
As at 1 November 2024 1,549,225
As at 31 October 2025 1,549,225
Provision
As at 1 November 2024 -
As at 31 October 2025 -
Net Book Value
As at 31 October 2025 1,549,225
As at 1 November 2024 1,549,225
5. Debtors
2025 2024
£ £
Due within one year
VAT 2,560 2,560
Called up share capital not paid 210,000,100 210,000,100
210,002,660 210,002,660
6. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Amounts owed to related parties 312,157 310,855
7. Share Capital
2025 2024
£ £
Called Up Share Capital not Paid 210,000,100 210,000,100
Amount of Allotted, Called Up Share Capital 210,000,100 210,000,100
Page 2